

26. (New) A transgenic mouse whose genome comprises a disruption in an endogenous CRFR2 gene, wherein where the disruption is homozygous, the transgenic mouse exhibits decreased susceptibility to seizure, relative to a wild-type mouse.

27. (New) The transgenic mouse of claim 26, wherein the decreased susceptibility to seizure is characterized by the transgenic mouse requiring a higher dose of metrazol to elicit a seizure response.

28. (New) A method of producing a transgenic mouse comprising a disruption in an endogenous CRFR2 gene, the method comprising:

- introducing a CRFR2 gene targeting construct into a murine embryonic stem cell;
- introducing the murine embryonic stem cell into a blastocyst;
- implanting the resulting blastocyst into a pseudopregnant mouse, wherein the pseudopregnant mouse gives birth to a chimeric mouse; and
- breeding the chimeric mouse to produce the transgenic mouse,

wherein where the disruption is homozygous, the transgenic mouse exhibits decreased activity or decreased susceptibility to seizure, relative to a wild-type mouse.

29. (New) The transgenic mouse produced by the method of claim 28.

In the Specification:

Please replace the paragraph beginning at page 11, line 5 of the specification (Brief Description of the Drawings) with the following paragraph:

--Figure 2A shows the design of the targeting construct used to disrupt CRFR2 genes (SEQ ID NO:1), including the location and extent of the disrupted portion of the CRFR2 gene, as well as the nucleotide sequences flanking the deleted portion. Figure 2B shows the sequences identified as SEQ ID NO:2 and SEQ ID NO:3, which were used as the 5'- and 3'- targeting arms (including the homologous sequences) in the CRFR2 targeting construct, respectively.--

In the Drawings:

Please replace originally filed Figure 2A with new Figure 2A enclosed herewith. A marked-up copy of original Figure 2A with the corrections indicated in red ink has been enclosed, along with a clean version of new Figure 2A.